Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Subjects

Trial Profile

Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2012

At a glance

  • Drugs Clopidogrel; Omeprazole; Rabeprazole
  • Indications Atherosclerosis; Duodenal ulcer; Embolism and thrombosis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Ischaemic heart disorders; Myocardial infarction; Peptic ulcer; Peripheral arterial occlusive disorders; Unstable angina pectoris; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics
  • Acronyms CLARA
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 10 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 10 Jun 2010 Actual patient number (39) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top